简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用

doi:10.3877/cma.j.issn.1674-3946.2024.04.022

目的

比较简化肝脏核磁共振成像（MRI）方案和标准肝脏MRI方案在评估疾病的存在、节段受累和对化疗的反应及手术计划方面对比，用于结直肠癌肝转移的治疗后随访。

方法

回顾性分析2020年1月至2023年1月连续接受化疗的113例结直肠癌肝转移患者的临床资料，化疗前和化疗后8~12周分别进行简化和标准肝脏MRI方案。治疗后获得的图像，根据RECIST 1.1记录治疗反应。使用加权Cohen kappa统计量确定图像集之间的一致性水平，采用Friedman检验比较不同MRI评估疾病情况。P<0.05被认为差异有统计学意义。

结果

标准方案和简化方案的总转移数具有很高的一致性（组内相关系数=0.97）。各节段受累的加权κ为0.73-0.85，各节段的加权kappa值为0.82。节段受累的差异并没有改变潜在的手术计划。使用简化方案与标准方案对RECIST 1.1治疗反应进行分类显示出很好的一致性（加权κ=0.92）。

结论

简化肝脏MRI方案允许在化疗后进行评估，类似于标准肝脏MRI方案。使用简化的方案可以减少成像时间，而不会牺牲对结直肠癌肝转移的后续诊断性能。

关键词: 结直肠肿瘤, 肝转移, 磁共振成像, 疗效比较研究

Objective

The simplified hepatic magnetic resonance imaging (MRI) protocol was compared with the standard hepatic MRI protocol in assessing the presence of disease, segmental involvement, and response to chemotherapy, as well as surgical planning, for post-treatment follow-up of colorectal metastases.

Methods

Clinical data of 113 patients with liver metastases from colorectal cancer who received continuous chemotherapy from January 2020 to January 2023 were retrospectively analyzed. Simplified and standard liver MRI regimens were performed before chemotherapy and 8 to 12 weeks after chemotherapy. For images obtained after treatment, treatment responses were recorded according to RECIST 1.1. Weighted Cohen kappa statistics were used to determine the consistency level between image sets, and Friedman test was used to compare the disease assessment of different MRI. P<0.05 was considered statistically significant.

Results

The total transfer numbers of the standard scheme and the simplified scheme were highly consistent (intra-group correlation coefficient =0.97). The weighted κ of each segment was 0.73 to 0.85, and the weighted kappa of each segment was 0.82. The difference in segmental involvement did not alter the underlying surgical plan. Classification of response to RECIST 1.1 using simplified versus standard regiments showed good agreement (weighted κ=0.92).

Conclusion

The simplified liver MRI protocol allows evaluation after chemotherapy and is similar to the standard liver MRI protocol. Using a simplified protocol can reduce imaging time without sacrificing subsequent diagnostic performance for liver metastases in colorectal cancer.

Key words: Colorectal Neoplasms, Liver Metastases, Magnetic Resonance Imaging, Comparative Effectiveness Research

表1 两组患者MRI方案和反应类别的治疗反应[例（%）]

AMRI方案	SMRI方案
AMRI方案	PD	SD	PR	CR	合计
PD	24(10.6)	1(0.4)	0(0.0)	0(0.0)	25(11.1)
SD	1(0.4)	22(9.7)	4(1.8)	0(0.0)	27(11.9)
PR	0(0.0)	1(0.4)	172(76.1)	0(0.0)	173(76.6)
CR	0(0.0)	0(0.0)	0(0.0)	1(0.4)	1(0.4)
合计	25(11.1)	24(10.6)	176(77.9)	1(0.4)	226(100)

表1 两组患者MRI方案和反应类别的治疗反应[例（%）]

AMRI方案	SMRI方案
AMRI方案	PD	SD	PR	CR	合计
PD	24(10.6)	1(0.4)	0(0.0)	0(0.0)	25(11.1)
SD	1(0.4)	22(9.7)	4(1.8)	0(0.0)	27(11.9)
PR	0(0.0)	1(0.4)	172(76.1)	0(0.0)	173(76.6)
CR	0(0.0)	0(0.0)	0(0.0)	1(0.4)	1(0.4)
合计	25(11.1)	24(10.6)	176(77.9)	1(0.4)	226(100)

表2 两种方案判断肝段有无转移癌的结局对比（加权κ）

肝段	SMRI方案	AMRI方案	肝段	SMRI方案	AMRI方案
Ⅰ	0.73	0.82	Ⅶ	0.76	0.85
Ⅱ	0.83	0.87	Ⅷ	0.76	0.85
Ⅲ	0.85	0.85	组合段
Ⅳa	0.84	0.86	Ⅱ和Ⅲ	0.96
Ⅳb	0.85	0.81	Ⅳa和Ⅳb	0.94
V	0.78	0.90	Ⅴ和Ⅷ	0.95
Ⅵ	0.80	0.88	Ⅵ和Ⅶ	0.91

表2 两种方案判断肝段有无转移癌的结局对比（加权κ）

肝段	SMRI方案	AMRI方案	肝段	SMRI方案	AMRI方案
Ⅰ	0.73	0.82	Ⅶ	0.76	0.85
Ⅱ	0.83	0.87	Ⅷ	0.76	0.85
Ⅲ	0.85	0.85	组合段
Ⅳa	0.84	0.86	Ⅱ和Ⅲ	0.96
Ⅳb	0.85	0.81	Ⅳa和Ⅳb	0.94
V	0.78	0.90	Ⅴ和Ⅷ	0.95
Ⅵ	0.80	0.88	Ⅵ和Ⅶ	0.91

图1 肝窦梗阻综合征可降低MRI上病变显著性（74岁的结直肠癌肝转移患者，奥沙利铂治疗）注：A和B=MR图像的前处理，B值为750 s/mm²的DW像（A）和肝胆相（HBP）增强T1加权像（B）显示肝右静脉附近的小转移灶（箭头示）；C和D=化疗后MR图像。DW图像，b值为750 s/mm²（C），HBP加多西二钠增强T1加权像（D）。T1加权像上可见肝实质网状结构改变，转移不再表现为限制性扩散，由于背景肝脏的异质性，残余转移被漏诊。

图2 模拟血管转移瘤（71岁男性结直肠癌肝转移患者）注：A=MR图像的前处理。在基线T2加权像上，在II和Ⅷ节段（箭头示）可见两个转移癌；B-D=化疗后MR图像。B值为750 s/mm²（B）的DW图像显示，Ⅷ期转移灶对治疗有反应，不再显示限制扩散。在门静脉期T1加权像（C）上，作为标准MRI方案的一部分，两个转移癌都显示为低信号。在门静脉期，静脉返回高信号，这使静脉与转移癌区分开来。在肝胆期MR图像（D）中，转移癌和肝内静脉均返回低信号，导致读者在使用简化的肝脏MRI方案时将Ⅷ段转移癌误解为血管。

［1］	汪建林，李琳，宋文杰，等. 四种手术方式治疗结直肠癌肝转移的安全性及近期预后分析［J/CD］. 中华普外科手术学杂志（电子版），2021, 15（05）: 528-530.
［2］	党学宁，陈潇健，崔龙. 一碳单位的代谢与结直肠癌关系的研究进展［J/CD］. 中华普外科手术学杂志（电子版），2021, 15（04）: 468-472.
［3］	LI X，CHENG L，LI C，et al. Associating Preoperative MRI Features and Gene Expression Signatures of Early-stage Hepatocellular Carcinoma Patients using Machine Learning［J］. J Clin Transl Hepatol，2022, 10（1）: 63-71.
［4］	Masokano IB，Pei Y，Chen J，et al. Development and validation of MRI-based model for the preoperative prediction of macrotrabecular hepatocellular carcinoma subtype［J］. Insights Imaging，2022, 13（1）: 201.
［5］	Ranathunga D，Osman H，Islam N，et al. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study［J］. AJR Am J Roentgenol，2022, 218（3）: 462-470.
［6］	Zhang L，Cheng C，Li B，et al. Combined clinical features and MRI parameters for the prediction of VEGFR2 in hepatocellular carcinoma patients［J］. Front Oncol，2022, 12: 961530.
［7］	Wu Y，Zhu M，Liu Y，et al. Peritumoral Imaging Manifestations on Gd-EOB-DTPA-Enhanced MRI for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis［J］. Front Oncol，2022, 12: 907076.
［8］	Wei H，Yang T，Chen J，et al. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions［J］. Liver Int，2022, 42（10）: 2131-2144.
［9］	Wu H，Liang Y，Wang Z，et al. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma［J］. Acta Radiol，2023, 64（3）: 926-935.
［10］	Luo J，Huang Z，Wang M，et al. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy［J］. BMC Gastroenterol，2022, 22（1）: 108.
［11］	Cai S，Lin X，Sun Y，et al. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma［J］. Eur J Radiol，2022, 154: 110449.
［12］	Odedra D，Jandaghi AB，Bhayana R，et al. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation［J］. Cancer Imaging，2022, 22（1）: 55.
［13］	Kim YY，Lee S，Shin J，et al. Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies［J］. Eur Radiol，2022, 32（10）: 6723-6729.
［14］	Zhao Y，Huang F，Liu S，et al. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score［J］. J Cancer Res Clin Oncol，2023, 149（8）: 5181-5192.
［15］	Liu QP，Yang KL，Xu X，et al. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study［J］. Abdom Radiol（NY），2022, 47（2）: 651-663.
［16］	Hwang SH，Hong SB，Han K，et al. A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid-Enhanced MRI Features［J］. J Magn Reson Imaging，2022, 55（6）: 1877-1886.
［17］	Lu L，Pan X. Accuracy of Non-Contrast MRI for the Detection of Hepatocellular Carcinoma: A systematic review and meta-analysis［J］. Pak J Med Sci，2022, 38（3Part-I）: 743-750.
［18］	Shi H，Duan Y，Shi J，et al. Role of preoperative prediction of microvascular invasion in hepatocellular carcinoma based on the texture of FDG PET image: A comparison of quantitative metabolic parameters and MRI［J］. Front Physiol，2022, 13: 928969.
［19］	李丁昌，曹李，陈鹏，等. 结直肠癌肝转移多阶段机制研究进展［J/CD］. 中华普外科手术学杂志（电子版），2021, 15（06）: 696-699.

[1]	鲁鑫, 杨琴, 许佳怡. 不同术式治疗恶性梗阻性黄疸疗效及对免疫功能的影响[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 180-183.
[2]	张金珠, 杨明, 王锡山. 中国、美国及世界结直肠癌流行病学与疾病负担的对比和思考[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 89-93.
[3]	王文鹏, 邓露, 施丹, 胡均, 王捷夫, 云铎, 孔大陆. 脂肪酸分解代谢相关基因ABHD1和PLA2G15在结直肠癌不良预后及肿瘤进展中的研究[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 101-111.
[4]	邵文哲, 孙倩男, 王道荣. Galectin-9在结直肠癌中的表达及其临床意义[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 112-120.
[5]	王佳琦, 李兴源, 熊寰, 常泽文, 王子桐, 燕国庆, 丁可, 袁子茗, 乔天宇, 黄睿, 王贵玉, 汤庆超. 机器人手术系统辅助下的结直肠癌经自然腔道取标本手术与常规辅助切口取标本手术的近期疗效对比研究[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 121-128.
[6]	赵迪, 杨鑫鑫, 孟宏学. 液体活检技术在结直肠癌诊疗领域的应用[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 135-140.
[7]	顾纪明, 蒋晖, 金留根, 钱程佳, 陈柏, 谢立飞. 腹腔镜辅助结肠次全切除术治疗同时性多原发结直肠癌的应用体会[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 153-157.
[8]	张毅勋, 关旭, 焦帅, 张鑫, 刘茂希, 高晟, 冯毅, 王文渊, 江波, 白文启, 刘海义, 王锡山. 腔镜切割荷包吻合器在腹腔镜结直肠癌手术中的应用体会[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 148-152.
[9]	杨魁, 龚文斌, 余钧辉, 郑见宝, 孙学军, 赵伟. 腹部无辅助切口经阴道拖出标本的腹腔镜右半结肠癌根治术一例（附视频）[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 171-176.
[10]	卓长华, 叶韵斌, 陈昌江, 简锦亮, 王志纬. 林奇综合征相关性异时性结直肠癌的治疗[J]. 中华结直肠疾病电子杂志, 2024, 13(01): 32-37.
[11]	赵海清, 张威, 李琴. 肌苷联合免疫检查点抑制剂在转移性结直肠癌患者中的临床疗效观察[J]. 中华结直肠疾病电子杂志, 2024, 13(01): 54-62.
[12]	周大杨, 刘畅, 黄鉴, 许宁, 吉祥, 杨可欣, 彭继邦, 潘海, 徐文静, 珠珠. 一例携带BRCA1 p.R166fs新突变位点的结肠癌病例报道[J]. 中华结直肠疾病电子杂志, 2024, 13(01): 68-71.
[13]	张朋伟, 杨朝凤, 李杨. 结直肠癌肝转移介入治疗的研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(02): 177-182.
[14]	蒋启红, 任勇军. 钆塞酸二钠增强MRI在评估肝功能的研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(02): 183-187.
[15]	胡秀朝, 徐霁华, 米荷音, 郝咏刚, 秦伟, 王韵. 高分辨磁共振成像在颈部动脉夹层致脑卒中诊断及随访研究中的价值[J]. 中华脑血管病杂志(电子版), 2024, 18(02): 140-144.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical application of simplified and standard liver MRI protocols in follow-up of patients with liver metastases from colorectal cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical application of simplified and standard liver MRI protocols in follow-up of patients with liver metastases from colorectal cancer